Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas

碩士 === 國立中興大學 === 獸醫學系暨研究所 === 99 === Lymphoma is the most common hematopoietic malignancy in dogs, and immu-nophenotype is one of the most important prognostic factors studied in the past decade. Polymerase chain reaction (PCR) for antigen receptor rearrangement (PARR) has ex-panded the diagnosis a...

Full description

Bibliographic Details
Main Authors: Yi-Ping Yang, 楊伊平
Other Authors: Shih-Chieh Chang
Format: Others
Language:zh-TW
Published: 2011
Online Access:http://ndltd.ncl.edu.tw/handle/80362054180068739171
id ndltd-TW-099NCHU5541010
record_format oai_dc
spelling ndltd-TW-099NCHU55410102016-04-11T04:23:00Z http://ndltd.ncl.edu.tw/handle/80362054180068739171 Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas 犬淋巴瘤病患預後分析及以聚合酶鏈鎖反應與免疫組織化學染色方法鑑定腫瘤細胞來源及表現型 Yi-Ping Yang 楊伊平 碩士 國立中興大學 獸醫學系暨研究所 99 Lymphoma is the most common hematopoietic malignancy in dogs, and immu-nophenotype is one of the most important prognostic factors studied in the past decade. Polymerase chain reaction (PCR) for antigen receptor rearrangement (PARR) has ex-panded the diagnosis and clonality assay in canine lymphomas. The aim of this study was to define the prognostic variables among dogs that received different chemothera-peutic protocols, and to compare the sensitivity of immunohistochemical (IHC) staining with PCR assay in the determination of tumor lineage. Eighty multicentric and 10 primary cutaneous lymphomas were included. A single-agent doxorubicin protocol presented with a similar efficacy regarding the progression-free and survival times, whereas a significantly higher complete response (CR) rate, with the combination pro-tocol in dogs with multicentric lymphoma. Dogs with B-cell phenotype were 9 times as likely as dogs with T-cell phenotype to have a CR to chemotherapy in multicentric lymphomas (P = 0.089). Clinical substage, P-glycoprotein expression prior to chemo-therapy, and response to therapy were significantly associated with the survival time. Tumor lineage was determined in 66 lymphomas by IHC and PCR methods. As a result, multicentric lymphomas comprised 78.6% (44/56) B-cell and 12.5% (7/56) T-cell lymphomas, and 5 dogs (5/56; 8.9%) remained undetermined. All the 10 cutaneous lymphomas were of T-cell phenotype. Dual phenotype and genotype were separately found in two multicentric lymphomas. Overall, a higher sensitivity of IHC immuno-phenotyping than PCR clonality assay (93.4% versus 87.0%) in the determination of lineage was demonstrated in all lymphomas in the present study. Shih-Chieh Chang 張仕杰 2011 學位論文 ; thesis 72 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國立中興大學 === 獸醫學系暨研究所 === 99 === Lymphoma is the most common hematopoietic malignancy in dogs, and immu-nophenotype is one of the most important prognostic factors studied in the past decade. Polymerase chain reaction (PCR) for antigen receptor rearrangement (PARR) has ex-panded the diagnosis and clonality assay in canine lymphomas. The aim of this study was to define the prognostic variables among dogs that received different chemothera-peutic protocols, and to compare the sensitivity of immunohistochemical (IHC) staining with PCR assay in the determination of tumor lineage. Eighty multicentric and 10 primary cutaneous lymphomas were included. A single-agent doxorubicin protocol presented with a similar efficacy regarding the progression-free and survival times, whereas a significantly higher complete response (CR) rate, with the combination pro-tocol in dogs with multicentric lymphoma. Dogs with B-cell phenotype were 9 times as likely as dogs with T-cell phenotype to have a CR to chemotherapy in multicentric lymphomas (P = 0.089). Clinical substage, P-glycoprotein expression prior to chemo-therapy, and response to therapy were significantly associated with the survival time. Tumor lineage was determined in 66 lymphomas by IHC and PCR methods. As a result, multicentric lymphomas comprised 78.6% (44/56) B-cell and 12.5% (7/56) T-cell lymphomas, and 5 dogs (5/56; 8.9%) remained undetermined. All the 10 cutaneous lymphomas were of T-cell phenotype. Dual phenotype and genotype were separately found in two multicentric lymphomas. Overall, a higher sensitivity of IHC immuno-phenotyping than PCR clonality assay (93.4% versus 87.0%) in the determination of lineage was demonstrated in all lymphomas in the present study.
author2 Shih-Chieh Chang
author_facet Shih-Chieh Chang
Yi-Ping Yang
楊伊平
author Yi-Ping Yang
楊伊平
spellingShingle Yi-Ping Yang
楊伊平
Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
author_sort Yi-Ping Yang
title Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
title_short Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
title_full Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
title_fullStr Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
title_full_unstemmed Prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
title_sort prognostic variables, and clonality and pheno-typing by polymerase chain reaction and immu-nohistochemical methods in canine lymphomas
publishDate 2011
url http://ndltd.ncl.edu.tw/handle/80362054180068739171
work_keys_str_mv AT yipingyang prognosticvariablesandclonalityandphenotypingbypolymerasechainreactionandimmunohistochemicalmethodsincaninelymphomas
AT yángyīpíng prognosticvariablesandclonalityandphenotypingbypolymerasechainreactionandimmunohistochemicalmethodsincaninelymphomas
AT yipingyang quǎnlínbāliúbìnghuànyùhòufēnxījíyǐjùhéméiliànsuǒfǎnyīngyǔmiǎnyìzǔzhīhuàxuérǎnsèfāngfǎjiàndìngzhǒngliúxìbāoláiyuánjíbiǎoxiànxíng
AT yángyīpíng quǎnlínbāliúbìnghuànyùhòufēnxījíyǐjùhéméiliànsuǒfǎnyīngyǔmiǎnyìzǔzhīhuàxuérǎnsèfāngfǎjiàndìngzhǒngliúxìbāoláiyuánjíbiǎoxiànxíng
_version_ 1718221714070962176